Phio Pharmaceuticals Corp. (PHIO) — Financial statements
Income statement, balance sheet, and cash flow for Phio Pharmaceuticals Corp. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 0.00↓100.0% | 4↓42.5% | 6↓9.7% | 7↓21.1% | 9 | |
| Gross Profit | 0.00↑100.0% | -4↑42.5% | -6↑9.7% | -7↑21.1% | -9 | |
| Operating Expenses | ||||||
| R&D Expenses | 5↑26.8% | 4↓42.5% | 6↓9.7% | 7↓21.1% | 9 | |
| General & Administrative Expenses | 5↑22.9% | 4↓12.7% | 4↓3.6% | 4↓3.8% | 5 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 5↑22.9% | 4↓12.7% | 4↓3.6% | 4↓3.8% | 5 | |
| Other Expenses | 0.00↑100.0% | -4↑40.6% | -6↑12.6% | -7↑21.1% | -9 | |
| Operating Expenses | 9↑146.3% | 4↓16.7% | 4↑0.9% | 4↓3.8% | 5 | |
| Total Costs & Expenses | 9↑24.8% | 7↓31.8% | 11↓5.6% | 11↓15.2% | 14 | |
| Operating Results | ||||||
| Operating Income | -9↓24.8% | -7↑31.8% | -11↑5.6% | -11↑15.2% | -14 | |
| Depreciation & Amortization | 0.00↑50.0% | 0.00↓98.9% | 0.18↑159.2% | 0.07↓5.3% | 0.08 | |
| EBITDA | -9↓24.8% | -7↑30.6% | -11↑6.6% | -11↑15.2% | -13 | |
| EBIT | -9↓24.8% | -7↑31.8% | -11↑5.5% | -11↑15.2% | -14 | |
| Interest & Other Income | ||||||
| Net Interest Income | 0.00↓100.0% | 0.23 | 0.00 | 0.00 | 0.00 | |
| Interest Income | 0.00↓100.0% | 0.23 | 0.00 | 0.00 | 0.00 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | 0.00 | 0.00↓100.0% | 0.00 | 0.00 | 0.00 | |
| Other Income / Expenses | 0.52↑120.3% | 0.24↑11950.0% | -0.00↑88.9% | -0.02↓108.0% | 0.22 | |
| Income Before Tax | -9↓21.7% | -7↑34.0% | -11↑5.7% | -11↑13.6% | -13 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -9↓21.7% | -7↑34.0% | -11↑5.7% | -11↑13.6% | -13 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -9↓21.7% | -7↑34.0% | -11↑5.7% | -11↑13.6% | -13 | |
| Bottom-Line Net Income | -9↓21.7% | -7↑34.0% | -11↑5.7% | -11↑13.6% | -13 | |
| EPS (Basic) | -1.45↓59.3% | -0.91↑98.1% | -46.87↑47.7% | -89.61↑19.5% | -111.32 | |
| EPS (Diluted) | -1.45↓59.3% | -0.91↑98.1% | -46.76↑47.8% | -89.61↑19.5% | -111.32 | |
| Weighted Average Shares | 6↑659.9% | 0.79↑240.9% | 0.23↑83.1% | 0.13↑6.3% | 0.12 | |
| Weighted Average Diluted Shares | 6↑659.9% | 0.79↑240.1% | 0.23↑83.5% | 0.13↑6.3% | 0.12 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.